Grzyby lecznicze i jadalne. Cz. I

• Autorzy: Busch E. , Wantoch von Rekowski R. , Altenbach H.J. , Moelleken H. , Burczyk J. , Malinowska E. , Krzyczkowski W.

Warianty tytułu

EN

Therapeutic and edible mushrooivis. Part I

• Języki publikacji: PL

Abstrakty

PL

Omówiono stan badań dotyczący aktywności terapeutycznej 8 ważniejszych grzybów leczniczych z rodzaju: Lentinus, Grifolia, Pleurotus, Flammulina, Agaricus, Hirneola (Auricularia) oraz Ganoderma. W szczególności omówiono działanie immunostymulujace i przeciwnowotworowe. Za wspomniane działania są głównie odpowiedzialne glikoproteiny Ulub polisacharydy zazwyczaj typu ß-l,3-glukanu. Przedstawiono przykłady hodowli przemysłowej wspomnianych grzybów.

EN

The publication gives a review of therapeutic activities of 8 edible mushrooms. These are members of the genus: Lentinus, Grifolia, Pleurotus, Flammulina, Agaricus, Hirneola (Auricularia) and Ganoderma. Particularly discussed are the immunomodulatory and antineoplastic acitivities. These are related mainly to ß-l,3-glucans, which act on the immune system. In some cases the large scale production of mushrooms was shown.

Słowa kluczowe

PL

Agaricus; Flammulina; Ganoderma; Grifolia; Lentinus; beta-1,3-glukany; dzialanie przeciwnowotworowe; glikoproteiny; grzyby jadalne; grzyby lecznicze; immunomodulatory; wielocukry; substancje biologicznie czynne; polisacharydy; leczenie

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2010
• Tom: 37
• Numer: 1
• Opis fizyczny: s.37-50,rys.,tab.,bibliogr.

Twórcy

autor

Busch E.

• Mykomax Gmbh, Wuppertal

autor

Wantoch von Rekowski R.

autor

Altenbach H.J.

autor

Moelleken H.

autor

Burczyk J.

autor

Malinowska E.

autor

Krzyczkowski W.

Bibliografia

• 2. Hobbs C.: Medicinal value of Lentinus edodes (Berk.) Sing. (Agaricomycetide- ae). A literature review. International Journal of Medicinal Mushrooms, 2000, 2, 287-302
• 3. Naturheilkundelexikon.de - (C) MZ-Verlag Ltd, 2005.
• 9. Ikekawa T.: Beneficial effects of edible and medicinal mushrooms in health care. International Journal of Medicinal Mushrooms, 2001, 3, 291-298.
• 10. Wasser S.P.: Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Applied Microbiology and Biotechnology, 2002, 60, 258-274.
• 15. Zhang L. i wsp.: Correlation between antitumor activity, molecular weight, and conformation of lentinan. Carbohydrate Research, 2005, 340(8), 1515-1521.
• 16. Nagashima Y. i wsp.: Evaluation of host immunity and side effects in breast cancer patients treated with adjuvant chemotherapy (FEC therapy) Gan to kagaku ryoho. Cancer & Chemotherapy, 2005, 32(11), 1550-1552.
• 22. Lindequist U., Niedermeyer T.H.J., Julich W.D.: Review: The pharmacological potential of mushrooms. Evidence-based Complementary and Alternative Medicine, 2005, 2(3), 285-299.
• 23. Drandarska I. i wsp.: Combined immunomodulating effects of BCG and Lentinan after intranasal application in guinea pigs. International Immunopharmacology, 2005, 5(4), 795-803.
• 25. Fang N. i wsp.: Inhibition of growth and induction of apoptosis in human cancer cell lines by an ethyl acetate fraction from shiitake mushrooms. Journal of Alternative and Complementary Medicine, 2006, 12(2), 125-132
• 29.Chen J.,Sevio- ur R.: Medicinal importance of fungal beta-(l?3),(l?6)glucans. Mycol.Res. (2007) 111(6),635-652.
• 40. Kodama N. i wsp.: Effects of D-fraction, a polysaccharide from Grifola fron- dosa on tumor growth involve activation of NK cells. Biological and Pharmaceutical Bulletin, 2002, 25, 1647-1650.
• 41. Kodama N., Komuta K., Nanba H.: Effect of maitake (Grifola frondosa) D-fraction on the activation of NK cells in cancer patients. Journal of Medicinal Food, 2003, 6, 371-3771.
• 44. Kodama N., Komuta K., Nanba H.: Can maitake MD-fraction aid cancerpatients? Alternative Medicine Review, 2002, 7, 236-239.
• 45. Borchers A.T., Keen C.L.,Gershwin M.E.: Mushrooms, tumors, and immunity: an update. Experimental Biology and Medicine, 2004, 229, 393-406.
• 46. Konno S. i wsp.: Anticancer and hypoglycemic effects of polysaccharides in edible and medicinal Maitake mushroom -Grifola frondosa (Dicks.:Fr.) S.F.Gray], International Journal of Medicinal Mushrooms, 2002, 4, 185-195.
• 47. Lindequist U. i wsp.: Review: The pharmacological potential of mushrooms. Evidence-based Complementary and Alternative Medicine, 2005, 2(3) 285-299.
• 48. Cunningham-Rundles S., Lin H., Cassileth B.: Immunonutrition: Enhancing tumo- ricidal cell activity. Are botanical glucans effective in enhancing tumoricidal cell activity? American Society for Nutrition. Journal of Nutrition, 2005, 135, 2919.
• 49. Lin H. i wsp.: Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro. International Immunopharmacology, 2004, 4(1), 91-99.
• 50. Lin H. i wsp.: Enhancement of umbilical cord blood cell hematopoiesis by maitake Beta-glucan is mediated by granulocyte colony-stimulating factor production. Clinical and Vaccine Immunology, 2007, 14(1), 21-27.
• 51. Kodama N. i wsp.: Maitake D-Fraction enhances antitumor effects and reduces immunosuppression by mitomycin-C in tumor-bearing mice. Nutrition, 2005, 21(5), 624-629.
• 52. Kodama N. i wsp.: Enhancement of cytotoxicity of NK cells by D-Fraction, a polysaccharide from Grifola frondosa. Oncology Reports, 2005, 13(3), 497-502.
• 53. Gu C.Q., Li J.W., Chao F.H.: Inhibition of hepatitis B virus by D-fraction from Grifola frondosa: synergistic effect of combination with interferon-alpha in HepG2 2.2.15. Antiviral Research, 2006, 72(2), 162-165.
• 54. Spelman K. i wsp.: Modulation of cytokine expression by traditional medicines: a review of herbal immuno- modulators. Alternative medicine review: A Journal of Clinical Therapeutic, 2006, 11(2), 128-150.
• 55. Wu M.J. i wsp.: Immunomodulatory properties of Grifola frondosa in submerged culture. Journal of Agricultural and Food Chemistry, 2006, 54(8), 2906-2914.
• 56. Cui F.J. i wsp.: Structural analysis of anti-tumor heteropolysaccharide GFPSlb from the cultured mycelia of Grifola frondosa GF9801. Bioresource Technology, 2007, 98(2), 395-401.
• 57. Naturheilkundelexikon.de - (C) MZ-Verlag Ltd, 2005.
• 64. Ooi VE.C., Liu F.: Immunomodulation and anti-cancer activity of polysaccharideprotein complexes. Current Medicinal Chemistry, 2000, 7, 715-729.
• 65. Wang H., Gao J., Ng T.B.: A new lectin with highly potent antihepatoma and antisarcoma activities from the oyster mushroom Pleurotus ostreatus. Biochemical and Biophysical Research Communications, 2000, 275(3), 810-816.
• 68. Taira K. i wsp.: Novel antimutagenic factors derived from the edible mushroom Agrocybe cy- lindracea. Mutation Research, 2005, 586(2), 115-123.
• 69. Lakshmi B. i wsp.: Antimutagenic activity of methanolic extract of culinary-medicinal oyster mushroom, Pleurotus ostreatus (Jacq.:Fr.) Kumm. (strain floric Eger nom. Nud.) and its protective effect against benzo-a.pyrene-induced hepatic damages. International Journal of Medicinal Mushrooms, 2004, 6, 139-149.
• 70. Lavi I. i wsp.: Schwartz: aqueous polysaccharide extract from the edible mushroom Pleurotus ostreatus induces anti-proliferative and pro-apoptotic effects on HT-29 colon cancer cells. Cancer Letters, 2006, 244(1), 61-70.
• 71. Gu Y.H., Sivam G.: Cytotoxic effect of oyster mushroom Pleurotus ostreatus on human androgen-in- dependent prostate cancer PC-3 cells. Journal of Medicinal Food, 2006, 9(2), 196- 204.
• 72. Sarangi I. i wsp.: Anti-tumor and immunomodulating effects of Pleurotus ostreatus mycelia-derived proteoglycans. International Immunopharmacology, 2006, 6(8), 1287-1297.
• 74. Bobek R, Galbavy S.: Effect of pleuran (beta-glucan from Pleurotus ostreatus) on the antioxidant status of the organism and on dime- thylhydrazine-induced precancerous lesions in rat colon. British Journal of Biomedical Science, 2001, 58(3), 164-168.
• 80. Hossain S. i wsp.: Dietary mushroom (Pleurotus ostreatus) ameliorates atherogenic lipid in hypercholesterolaemic rats. Clinical and Experimental Pharmacology and Physiology, 2003, 30(7), 470-475(6).
• 81. Jayakumar T., Aloysius Thomas E, Geraldine P: Protective effect of an extract of the oyster mushroom, Pleurotus ostreatus, on antioxidants of major organs of aged rats. Experimental Gerontology, 2007, 42(3), 183-191.
• 82. Jayakumar T., Ramesh E., Geraldine E: Antioxidant activity of the oyster mushroom, Pleurotus ostreatus, on CCl(4)-induced liver injury in rats. Food and Chemical Toxicology, 2006, 44(12), 1989-1996.
• 84. Monro J.A.: Treatment of cancer with mushroom products. Archives of Environmental Health, 2003, 58(8), 533-537.
• 91. Paaven- than E i wsp.: A 1.7A structure of Fve, a member of the new fungal immunomodulatory protein family. Journal of Molecular Biology, 2003, 332(2), 461-470.
• 93. Ike- kawa T.: Beneficial effects of edible and medicinal mushrooms in health care. International Journal of Medicinal Mushrooms, 2001, 3, 291-298.
• 94. Wasser S.E: Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Applied Microbiology and Biotechnology, 2002, 60, 258- 274.
• 95. Shi Y.L. i wsp.: Mushroom-derived preparations in the prevention of H202-induced oxidative damage to cellular DNA. Teratogenesis, Carcinogenesis, Mutagenesis, 2002, 22(2), 103-111.
• 96. Fukushima M. i wsp.: Cholesterol-lowering effects of maitake (Grifola frondosa) fiber, shiitake (Lentinus edodes) fiber, and enokitake (Flammulina velutipes) fiber in rats. Experimental Biology and Medicine, 2001, 226(8), 758-765.